Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Susan P Sambol"'
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0270119 (2022)
Nontoxigenic Clostridioides difficile strain M3 (NTCD-M3) protects hamsters and humans against C. difficile infection. Transfer in vitro of the pathogenicity locus (PaLoc) to nontoxigenic strain CD37 has been reported. We repeated these conjugations
Externí odkaz:
https://doaj.org/article/43c66f3c0a944fbf884c60c8136d52e9
Autor:
Andrew M. Skinner, Laurica Petrella, Farida Siddiqui, Susan P. Sambol, Christopher A. Gulvik, Dale N. Gerding, Curtis J. Donskey, Stuart Johnson
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 2, Pp 247-254 (2020)
During a surveillance study of patients in a long-term care facility and the affiliated acute care hospital in the United States, we identified a Clostridioides difficile strain related to the epidemic PCR ribotype (RT) 027 strain associated with hos
Externí odkaz:
https://doaj.org/article/945053626e5949daad101134aa64833f
Autor:
Susan P. Sambol, Andrew M. Skinner, Fidel Serna-Perez, Benjamin Owen, Dale N. Gerding, Stuart Johnson
Publikováno v:
Microbiology Spectrum. 11
NTCD-M3 is a novel live biotherapeutic, that has been shown in a Phase 2 clinical trial to prevent recurrence of C. difficile infection (CDI) when administered shortly after antibiotic treatment of the initial CDI episode. Fidaxomicin was not, howeve
Autor:
Laurent Chesnel, Julia Nary, Adam Cheknis, Susan P Sambol, Richard V. Goering, Stuart Johnson, Dominique Devaris, Suzanne E. Dale, Diane M. Citron
Publikováno v:
Journal of Antimicrobial Chemotherapy. 75:3120-3125
Objectives To investigate the molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile isolates from patients with C. difficile infection (CDI) from two Phase 3 clinical trials of surotomycin. Methods In both trials [Protoc
Autor:
Christopher W. Woods, Nan Hu, Susan M. Pacheco, Annette Jencson, Kalpana Gupta, Jeanmarie Mayer, Judith Strymish, David L. Johnson, Dale N. Gerding, Molly Leecaster, Nimalie D. Stone, Warren B. P. Pettey, Curtis J. Donskey, Matthew H. Samore, Susan P. Sambol, Edward J. Young, L. Clifford McDonald
Publikováno v:
American Journal of Infection Control. 48:626-632
Background Clostridioides difficile infection (CDI) causes significant morbidity in nursing home residents. Our aim was to describe adherence to a bundled CDI prevention initiative, which had previously been deployed nationwide in Veterans Health Adm
Autor:
S Tyler Phillips, Susan P. Sambol, Andrew M. Skinner, Kevin J. O'Leary, Stuart Johnson, Michelle M. Merrigan, Farida Siddiqui, Dale N. Gerding, Lance R. Peterson
Publikováno v:
Journal of Clinical Medicine
Volume 10
Issue 1
Journal of Clinical Medicine, Vol 10, Iss 96, p 96 (2021)
Volume 10
Issue 1
Journal of Clinical Medicine, Vol 10, Iss 96, p 96 (2021)
Most pathogenic strains of C. difficile possess two large molecular weight single unit toxins with four similar functional domains. The toxins disrupt the actin cytoskeleton of intestinal epithelial cells leading to loss of tight junctions, which ult
Autor:
Andrew M, Skinner, S Tyler, Phillips, Michelle M, Merrigan, Kevin J, O'Leary, Susan P, Sambol, Farida, Siddiqui, Lance R, Peterson, Dale N, Gerding, Stuart, Johnson
Publikováno v:
Journal of Clinical Medicine
Most pathogenic strains of C. difficile possess two large molecular weight single unit toxins with four similar functional domains. The toxins disrupt the actin cytoskeleton of intestinal epithelial cells leading to loss of tight junctions, which ult
Autor:
Emma L. Best, Mary Beth Dorr, Ellie J. C. Goldstein, Karen Eves, Stuart Johnson, Susan P. Sambol, Mark H. Wilcox, Dale N. Gerding, Diane M. Citron, Erin Jensen
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(9)
Background Bezlotoxumab reduced rates of recurrent Clostridioides difficile infection (rCDI) vs placebo in Monoclonal Antibodies for C. difficile Therapy (MODIFY) I/II trial participants receiving antibacterial drug treatment for CDI. A secondary obj
Autor:
Curtis J. Donskey, Stuart Johnson, Laurica A. Petrella, Susan P. Sambol, Farida Siddiqui, Christopher A. Gulvik, Dale N. Gerding, Andrew M Skinner
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 26, Iss 2, Pp 247-254 (2020)
Emerging Infectious Diseases, Vol 26, Iss 2, Pp 247-254 (2020)
During a surveillance study of patients in a long-term care facility and the affiliated acute care hospital in the United States, we identified a Clostridioides difficile strain related to the epidemic PCR ribotype (RT) 027 strain associated with hos
Publikováno v:
Frontiers in Microbiology
Frontiers in Microbiology, Vol 9 (2018)
Frontiers in Microbiology, Vol 9 (2018)
The beneficial effect of colonization of the gastrointestinal tract by non-toxigenic Clostridioides difficile (NTCD) strains as a preventive of toxigenic C. difficile infection (CDI) has been known since the early 1980s. Investigators in both the USA